Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485990 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL25439225 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL26231710 | 0.91 | AKT1 (0.37) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL22596587 | 0.91 | AKT1 (0.37) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL21276395 | 0.89 | AKT1 (0.36) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL20436175 | 0.89 | AKT1 (0.36) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL24497006 | 0.89 | AKT1 (0.36) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL21276367 | 0.89 | AKT1 (0.36) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL20436320 | 0.89 | AKT1 (0.36) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 | |
| SCHEMBL20436176 | 0.89 | PTGS1 (0.40) | PTGS1PTGS2FAAHAKT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136605-A1 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4365173-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117813287-A | Improved process for the preparation of cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3880656-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3880656-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230286914-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286914-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286914-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4148044-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11591296-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-10913713-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10844078-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844078-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-06-04 | — | — | US | disclosed |
| WO-2020102053-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10385071-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385071-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180251474-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2018-09-06 | — | — | US | disclosed |
| WO-2018140435-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286914-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
| US-10913713-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
| US-10844078-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
| US-20180251474-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
| US-10385071-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
| US-11591296-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
| US-20250136605-A1 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA4 | PTGS1 2843/4885PTGS2 2803/4885FAAH 1192/4885 |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTGS1 2639/4885PTGS2 2377/4885FAAH 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.